Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Memantine Therapy for Multiple Sclerosis (Memantine-MS)

This study has been terminated.
(Unexpected side-effects: reversible and mild to moderate neurological impairment)
Sponsor:
Collaborator:
H. Lundbeck A/S
Information provided by (Responsible Party):
Clinica Universidad de Navarra, Universidad de Navarra
ClinicalTrials.gov Identifier:
NCT00638833
First received: March 12, 2008
Last updated: June 7, 2012
Last verified: June 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: March 2008
  Primary Completion Date: March 2008 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):